Meredith S Irwin1, Arlene Naranjo2, Fan F Zhang3, Susan L Cohn4, Wendy B London5, Julie M Gastier-Foster6,7, Nilsa C Ramirez6,7, Ruthann Pfau6,7, Shalini Reshmi6,7, Elizabeth Wagner6, Jed Nuchtern8, Shahab Asgharzadeh9, Hiroyuki Shimada10, John M Maris11, Rochelle Bagatell11, Julie R Park12, Michael D Hogarty11. 1. Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada. 2. Children's Oncology Group Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, FL. 3. Children's Oncology Group Statistics and Data Center, Monrovia, CA. 4. Department of Pediatrics, The University of Chicago, Chicago, IL. 5. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA. 6. Institute for Genomic Medicine and Biopathology Center, Nationwide Children's Hospital, Columbus, OH. 7. Departments of Pathology and Pediatrics, Ohio State University, Columbus, OH. 8. Division of Pediatric Surgery, Department of Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX. 9. Division of Hematology/Oncology, Children's Hospital of Los Angeles, Los Angeles, CA. 10. Departments of Pathology and Pediatrics, Stanford University, Stanford, CA. 11. Department of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 12. Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA.
Abstract
PURPOSE: Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by the International Neuroblastoma Staging System. Here, we validate a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) and incorporate segmental chromosome aberrations (SCA) as an additional genomic biomarker. METHODS: Newly diagnosed patients enrolled on the COG neuroblastoma biology study ANBL00B1 between 2007 and 2017 with known age, International Neuroblastoma Staging System, and INRGSS stage were identified (N = 4,832). Tumor MYCN status, ploidy, SCA status (1p and 11q), and International Neuroblastoma Pathology Classification histology were determined centrally. Survival analyses were performed for combinations of prognostic factors used in COG risk classification according to the prior version 1, and to validate a revised algorithm (version 2). RESULTS: Most patients with locoregional tumors had excellent outcomes except for those with image-defined risk factors (INRGSS L2) with MYCN amplification (5-year event-free survival and overall survival: 76.3% ± 5.8% and 79.9% ± 5.5%, respectively) or patients age ≥ 18 months with L2 MYCN nonamplified tumors with unfavorable International Neuroblastoma Pathology Classification histology (72.7% ± 5.4% and 82.4% ± 4.6%), which includes the majority of L2 patients with SCA. For patients with stage M (metastatic) and MS (metastatic, special) disease, genomic biomarkers affected risk group assignment for those < 12 months (MYCN) or 12-18 months (MYCN, histology, ploidy, and SCA) of age. In a retrospective analysis of patient outcome, the 5-year event-free survival and overall survival using COG version 1 were low-risk: 89.4% ± 1.1% and 97.9% ± 0.5%; intermediate-risk: 86.1% ± 1.3% and 94.9% ± 0.8%; high-risk: 50.8% ± 1.4% and 61.9% ± 1.3%; and using COG version 2 were low-risk: 90.7% ± 1.1% and 97.9% ± 0.5%; intermediate-risk: 85.1% ± 1.4% and 95.8% ± 0.8%; high-risk: 51.2% ± 1.4% and 62.5% ± 1.3%, respectively. CONCLUSION: A revised 2021 COG neuroblastoma risk classifier (version 2) that uses the INRGSS and incorporates SCAs has been adopted to prospectively define COG clinical trial eligibility and treatment assignment.
PURPOSE: Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by the International Neuroblastoma Staging System. Here, we validate a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) and incorporate segmental chromosome aberrations (SCA) as an additional genomic biomarker. METHODS: Newly diagnosed patients enrolled on the COG neuroblastoma biology study ANBL00B1 between 2007 and 2017 with known age, International Neuroblastoma Staging System, and INRGSS stage were identified (N = 4,832). Tumor MYCN status, ploidy, SCA status (1p and 11q), and International Neuroblastoma Pathology Classification histology were determined centrally. Survival analyses were performed for combinations of prognostic factors used in COG risk classification according to the prior version 1, and to validate a revised algorithm (version 2). RESULTS: Most patients with locoregional tumors had excellent outcomes except for those with image-defined risk factors (INRGSS L2) with MYCN amplification (5-year event-free survival and overall survival: 76.3% ± 5.8% and 79.9% ± 5.5%, respectively) or patients age ≥ 18 months with L2 MYCN nonamplified tumors with unfavorable International Neuroblastoma Pathology Classification histology (72.7% ± 5.4% and 82.4% ± 4.6%), which includes the majority of L2 patients with SCA. For patients with stage M (metastatic) and MS (metastatic, special) disease, genomic biomarkers affected risk group assignment for those < 12 months (MYCN) or 12-18 months (MYCN, histology, ploidy, and SCA) of age. In a retrospective analysis of patient outcome, the 5-year event-free survival and overall survival using COG version 1 were low-risk: 89.4% ± 1.1% and 97.9% ± 0.5%; intermediate-risk: 86.1% ± 1.3% and 94.9% ± 0.8%; high-risk: 50.8% ± 1.4% and 61.9% ± 1.3%; and using COG version 2 were low-risk: 90.7% ± 1.1% and 97.9% ± 0.5%; intermediate-risk: 85.1% ± 1.4% and 95.8% ± 0.8%; high-risk: 51.2% ± 1.4% and 62.5% ± 1.3%, respectively. CONCLUSION: A revised 2021 COG neuroblastoma risk classifier (version 2) that uses the INRGSS and incorporates SCAs has been adopted to prospectively define COG clinical trial eligibility and treatment assignment.
Authors: Navin Pinto; Jodi R Mayfield; Gordana Raca; Mark A Applebaum; Alexandre Chlenski; Madina Sukhanova; Rochelle Bagatell; Meredith S Irwin; Anthony Little; Jawhar Rawwas; Yasmin Gosiengfiao; Olivier Delattre; Isabelle Janoueix-Lerosey; Eve Lapouble; Gudrun Schleiermacher; Susan L Cohn Journal: Pediatr Blood Cancer Date: 2016-02-10 Impact factor: 3.167
Authors: Mary Lou Schmidt; Ashutosh Lal; Robert C Seeger; John M Maris; Hiroyuki Shimada; Maura O'Leary; Robert B Gerbing; Katherine K Matthay Journal: J Clin Oncol Date: 2005-08-22 Impact factor: 44.544
Authors: R P Castleberry; J Pritchard; P Ambros; F Berthold; G M Brodeur; V Castel; S L Cohn; B De Bernardi; C Dicks-Mireaux; D Frappaz; G M Haase; M Haber; D R Jones; V V Joshi; M Kaneko; J T Kemshead; P Kogner; R E Lee; K K Matthay; J M Michon; R Monclair; B R Roald; R C Seeger; P J Shaw; J J Shuster Journal: Eur J Cancer Date: 1997-10 Impact factor: 9.162
Authors: M L Schmidt; J N Lukens; R C Seeger; G M Brodeur; H Shimada; R B Gerbing; D O Stram; C Perez; G M Haase; K K Matthay Journal: J Clin Oncol Date: 2000-03 Impact factor: 44.544
Authors: Julie R Park; Rochelle Bagatell; Wendy B London; John M Maris; Susan L Cohn; Katherine K Mattay; Katherine M Mattay; Michael Hogarty Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Wayne H Liang; Sara M Federico; Wendy B London; Arlene Naranjo; Meredith S Irwin; Samuel L Volchenboum; Susan L Cohn Journal: JCO Clin Cancer Inform Date: 2020-10
Authors: G Schleiermacher; J Michon; A Ribeiro; G Pierron; V Mosseri; H Rubie; C Munzer; J Bénard; N Auger; V Combaret; I Janoueix-Lerosey; A Pearson; D A Tweddle; N Bown; M Gerrard; K Wheeler; R Noguera; E Villamon; A Cañete; V Castel; B Marques; A de Lacerda; G P Tonini; K Mazzocco; R Defferrari; B de Bernardi; A di Cataldo; N van Roy; B Brichard; R Ladenstein; I Ambros; P Ambros; K Beiske; O Delattre; J Couturier Journal: Br J Cancer Date: 2011-11-10 Impact factor: 7.640
Authors: M Fevzi Ozkaynak; Andrew L Gilman; Wendy B London; Arlene Naranjo; Mitchell B Diccianni; Sheena C Tenney; Malcolm Smith; Karen S Messer; Robert Seeger; C Patrick Reynolds; L Mary Smith; Barry L Shulkin; Marguerite Parisi; John M Maris; Julie R Park; Paul M Sondel; Alice L Yu Journal: Front Immunol Date: 2018-06-18 Impact factor: 7.561
Authors: Anoop Mayampurath; Siddhi Ramesh; Diana Michael; Liu Liu; Nicholas Feinberg; Meaghan Granger; Arlene Naranjo; Susan L Cohn; Samuel L Volchenboum; Mark A Applebaum Journal: JCO Clin Cancer Inform Date: 2021-12
Authors: Sophie K F De Salis; Lanxin Li; Zheng Chen; Kam Wa Lam; Kristen K Skarratt; Thomas Balle; Stephen J Fuller Journal: Int J Mol Sci Date: 2022-07-25 Impact factor: 6.208